Welcome to our dedicated page for Grifols S A news (Ticker: GRFS), a resource for investors and traders seeking the latest updates and insights on Grifols S A stock.
News about Grifols, S.A. (GRFS) centers on its role as a global healthcare company focused on plasma-derived medicines, transfusion medicine and biopharmaceutical innovation. Founded in Barcelona in 1909 and active in more than 110 countries, Grifols regularly reports developments that matter to investors, healthcare professionals and patients.
Company news often highlights regulatory milestones for its plasma-based therapies and immunoglobulin products. Recent announcements include U.S. Food and Drug Administration (FDA) decisions on the subcutaneous immunoglobulin XEMBIFY, a fibrin sealant for surgical bleeding, and Biotest’s intravenous immunoglobulin Yimmugo. Updates on partnerships, such as collaborations with BARDA on ocular surface immunoglobulin eye drops and with The Michael J. Fox Foundation on Parkinson’s disease biomarker research, also feature prominently.
From a corporate perspective, Grifols’ news flow includes quarterly and half‑year financial results, progress on its Value Creation Plan, changes in leverage and liquidity, and dividend decisions. Filings and press releases describe revenue growth led by the Biopharma segment, trends in immunoglobulin, albumin and Alpha‑1 franchises, and performance of its Diagnostic business. Governance-related items, including amendments to Board regulations and commentary from shareholders such as Mason Capital Management, appear in communications and can influence market perception.
On this page, readers can follow earnings releases, product and pipeline updates, strategic collaborations, governance developments and other material announcements related to Grifols’ operations and capital markets activity. For investors tracking GRFS, this news stream provides context on how the company’s plasma-derived medicines, diagnostics and research initiatives evolve over time.
Grifols has announced its acquisition of Alkahest, Inc. for $146 million, aimed at enhancing its research and development capabilities for age-related diseases. The transaction, debt-free and requiring no additional financing, is subject to antitrust approval and expected to finalize in early 2021. Alkahest specializes in therapies targeting the aging plasma proteome, with over 8,000 proteins identified, promising innovative therapeutic avenues. This strategic move is anticipated to provide synergies in drug development for unmet medical needs associated with aging.
Grifols has successfully delivered the first batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials, aimed at providing passive immunity against COVID-19. This therapy, developed from convalescent plasma, will undergo safety and efficacy trials this summer. Grifols' initiative is backed by collaborations with U.S. health agencies, including the FDA and NIH, with previous experience from the Ebola outbreak enhancing their response. This positions Grifols as a key player in addressing current and future viral threats through innovative therapies.
Grifols announced the publication of the AMBAR study results in a prestigious journal, demonstrating that plasma protein replacement therapy can delay cognitive decline in Alzheimer's patients. The study, which followed patients for 14 months, showed significant improvements compared to a control group, indicating the potential of plasma-derived therapies in addressing Alzheimer's disease. Grifols emphasizes its commitment to expanding research in this area, aiming to develop new therapies for Alzheimer's and other degenerative diseases.
Grifols has acquired a 10% stake in Bloodbuy, a cloud-based marketplace enhancing blood component distribution in the U.S. This strategic investment aims to improve access to vital blood products for hospitals and healthcare providers, addressing supply and demand challenges exacerbated by COVID-19. Grifols will gain a seat on Bloodbuy's Board of Directors to support its growth and gain insights into the blood-component market. Bloodbuy's platform is crucial in connecting blood centers and hospitals, aiming to reduce waste and improve the efficiency of blood supply management.
Grifols has announced a strategic acquisition of a plasma fractionation facility in Montreal, along with 11 collection centers in the U.S., for US$460 million. This move positions Grifols as the only large-scale commercial manufacturer of plasma products in Canada, with a planned fractionation capacity of 1.5 million liters/year. The acquisition aligns with Grifols' commitment to enhancing the availability of plasma-derived medicines and aims to support Canada’s self-sufficiency in healthcare. The transaction is anticipated to close by the end of 2020, pending regulatory approvals.